Document Detail


Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
MedLine Citation:
PMID:  19820225     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There have been steady efforts to develop a combined response index for systemic sclerosis (CRISS). A parallel and equally successful effort has been made by an Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis (EPOSS) to measure effect in treatment of pulmonary arterial hypertension of systemic sclerosis (PAH-SSc). CRISS conducted a Delphi process combined with expert review to identify 11 candidate domains for inclusion in a core set of outcomes for SSc clinical trials: soluble biomarkers, cardiac, digital ulcers, gastrointestinal, global health, health related quality of life (HRQOL) and function, musculoskeletal, pulmonary, Raynaud's, renal, and skin. Tools within domains were also agreed upon. Concentrating on one aspect of disease, PAH, EPOSS also conducted a Delphi process and judged the following domains as the most appropriate for randomized controlled trials in PAH-SSc: lung vascular/pulmonary arterial pressure, cardiac function, exercise testing; severity of dyspnea, discontinuation of treatment; quality of life/activities of daily living; global state; and survival. Possible useful tools within each domain were also agreed on. Patient derived, physician derived, and objective measures of response will be included and combined with the idea that each reflects different aspects of PAH (EPOSS) and overall disease (CRISS) although this assumption may not prove true and can be separated if statistically and clinically valid to do so. In either case, prospective studies will require measurement of all domains, and tools are required and will be developed to define appropriate combined measures of response. CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected.
Authors:
Dinesh Khanna; Oliver Distler; Jerome Avouac; Frank Behrens; Philip J Clements; Christopher Denton; Ivan Foeldvari; Edward Giannini; Doerte Huscher; Otylia Kowal-Bielecka; Daniel Lovell; Marco Matucci-Cerinic; Maureen Mayes; Peter A Merkel; Peter Nash; Christian F Opitz; David Pittrow; Lewis Rubin; James R Seibold; Virginia Steen; C Vibeke Strand; Peter S Tugwell; John Varga; Angela Zink; Daniel E Furst; ;
Related Documents :
15361865 - Inhaled nebulized nitrite is a hypoxia-sensitive no-dependent selective pulmonary vasod...
8633955 - Pulmonary endothelial permeability changes after major lung resection.
18055675 - Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dyspl...
1734655 - Relation of plain chest radiographic findings to pulmonary arterial pressure and arteri...
24687165 - Arterial stiffness and β-amyloid progression in nondemented elderly adults.
20168045 - Comparison of endothelium-related responses to nucleotides of dog and monkey cerebral a...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of rheumatology     Volume:  36     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-12     Completed Date:  2010-02-11     Revised Date:  2013-10-17    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  2356-61     Citation Subset:  IM    
Affiliation:
David Geffen School at University of California, Los Angeles, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic / standards*
Consensus
Delphi Technique
Disability Evaluation
Humans
Hypertension, Pulmonary / physiopathology,  psychology,  therapy*
Outcome Assessment (Health Care) / standards*
Quality of Life
Scleroderma, Systemic / physiopathology,  psychology,  therapy*
Severity of Illness Index*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
K23 AR053858-01A1/AR/NIAMS NIH HHS; U01 AR055057/AR/NIAMS NIH HHS; U01 AR055057/AR/NIAMS NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Progress in measurement instruments for acute and chronic gout studies.
Next Document:  Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.